Within this subgroup analysis from Arbeitsgemeinschaft Internistische Onkologie-pancreatic cancer ( AIO-PK0104 ) , no evidence supporting the use of hENT1 as a predictive biomarker for gemcitabine efficacy in patients with advanced pancreatic cancer was found .